Reductive Carboxylation of Glutamine as a Potential Target in AML


“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.”


BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”


In this new editorial, researchers Alessia Roma, Lawrence D. Goodridge and Paul A. Spagnuolo from the University of Guelph discuss acute myeloid leukemia (AML) — an aggressive cancer of the blood and bone marrow defined by poor patient outcomes and sub-optimal therapeutics. 


Recent advancements in our understanding of AML biology bring optimism to improving patient outcomes for this devastating disease. For example, the discovery and validation of metabolic vulnerabilities that are distinct to AML open new strategies for novel drug development. In fact, since 2017, a third of newly approved AML therapeutics have targeted metabolic abnormalities. Thus, further identification and elucidation of metabolic vulnerabilities in AML could lead to novel therapies aimed at improving patient outcomes. 


“One approach is to weaken tumor cell survival mechanisms. In this regard, exploring reductive carboxylation as a possible drug target could provide new avenues for optimizing existing treatments aimed at improving AML patient outcomes.”


Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28474


Correspondence to: Paul A. Spagnuolo


Email: [email protected] 


Keywords: acute myeloid leukemia, reductive carboxylation, metabolism, mitochondria, complex II


Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28474



About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open-access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.


To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

X, formerly known as Twitter






Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact [email protected].


Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC